You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

riTUXimab (subcut)

( rit-TUCKS-ee-mab )
Funding:
New Drug Funding Program
  • Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
  • Rituximab (Biosimilar IV) and Rituximab SC - Second Line - Chronic Lymphocytic Leukemia
  • Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
  • Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
  • Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia
  • Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
  • Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Venetoclax - Relapsed Chronic Lymphocytic Leukemia
  • Rituximab (Biosimilar IV) and Rituximab SC - HIV-Related Aggressive Histology B-cell Lymphoma
  • Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
Other Name(s): Rituxan® SC
Appearance: Clear, colourless to yellowish solution

You might also be interested in